| Genomic region | Event | Frequency | Effected genes |
References | Tumour suppressor gene(s) | Oncogene(s) |
| 1q10-q12, 1q21-q31 | Amp | 6–59% | | | [50, 55, 77, 82–84] | 3q13.31 | Del, LOH | 6–80% | LSAMP | | [44, 45, 49–55] | 5q21 | LOH | 62% | APC | | [109] | 6p12-p21 | Gain, Amp | 16–75% | | RUNX2, CDC5L, VEGFA, PIM1 | [9, 20, 45, 49, 65, 77, 78, 82, 89–92] | 6p22.3 | Gain, Amp | 60% | | E2F3 | [92] | 7p21 7q31 | Del Amp Del Amp | 36% 14% 41% 9% | | TWIST MET | [109] | 8q24.21 | Amp | 7–67% | | MYC | [20, 45, 49, 55, 71, 78, 81–83] | 8q24.4 | Mut | <5% | RECQL4 | | [85] | Gain | 33% | RECQL4 | | [27] | 9p21 | Del | 5–21% | p16/INK4A, p14/ARF, p15/INK4B | | [48, 60–63] | 10q26 | LOH | 60% | BUB3, FGFR2 | | [106] | 12q13 | Amp | 41% | | PRIM1 | [58] | 12q14 | Amp | 10% | | CDK4 | [45, 57] | 12q15 | Amp | 3–25% | | MDM2 | [47, 48, 57, 72, 73] | 13q14.2 | LOH | 19–67% | RB1 | | [43–55] | Mut | 25–35% | RB1 | | [46, 56] | 16q23.1-q23.2 | Del | 30% | WWOX | | [107] | 17p11.2-p12 | Amp | 20–78% | | COPS3, PMP22, MAPK7 | [20, 49, 52, 55, 65, 68, 70, 75–80] | 17p13.1 | Del, LOH | 29–42% | TP53 | | [44, 62, 65] | Mut | 10–39% | TP53 | | [25, 44, 47, 48, 56, 62, 67–71] | 18q (MCR 18q21-q23) | Del | 31–64% | | | [44, 53, 110, 114] |
|
|